Schlosser Mario sold $4.3M of OSCR (indirect holdings)

Schlosser Mario sold 147,500 indirectly-held shares of Oscar Health, Inc. (OSCR) at an average of $29.38 ($28.95–$30.09, $4.33M total) across 9 trades on 2026-06-23 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Schlosser Mario
Published Jun 25, 2026, 8:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 25, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OSCR
Neutral
medium confidence
Mentioned
$OSCR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OSCRNeutralLow
01

Why it matters

A director sold 147,500 shares in open-market transactions at $28.9500–$30.0900 (weighted avg $29.3756), totaling ~$4.33M, under a pre-arranged Rule 10b5-1 plan; this is a sentiment datapoint rather than a fundamental catalyst.

02

Market read

Traders may monitor for follow-on insider activity, but the 10b5-1 framing suggests limited incremental information.

03

What to watch

The insider’s holdings drop to 0 shares, which can be interpreted as completion of a planned liquidity event; without additional context (e.g., other insiders, guidance), the trading signal is weak.

Relevance 5/10Novelty 5/10Timing: after-hours/filing update on June 25 (Form 4 filed)

Background

The article is an SEC Form 4 insider transaction for Oscar Health, Inc. (OSCR) by director Mario Schlosser.

Company-level read

Ticker impact

$OSCRNeutralMedium confidence
Context

Oscar Health disclosed a director open-market sale of 147,500 shares via a 10b5-1 plan, worth about $4.33M, filed June 25.

Expected impact

Likely limited immediate price impact; any effect would be sentiment-driven and modest unless accompanied by other news.

Evidence & confidence

The filing is a primary Form 4 disclosure with transaction size and pricing range, but it explicitly states a pre-arranged 10b5-1 plan and the insider ends with 0 shares.

Market effects

No direct sector read-through; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan and the trades occurred on June 23, the disclosure may be largely mechanical rather than a forward-looking bearish signal.

Key entities

  • Oscar Health, Inc.

    Subject of the Form 4 insider transaction; director sold shares under a 10b5-1 plan.

  • Mario Schlosser

    Director who executed the open-market sale; holdings after transaction: 0 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$UNHMed

Medicare, Medicaid Overhaul Targets Fraudulent Billing and Unauthorized Marketplace Enrollments

CMS proposed reforms to combat fraud in Medicare, Medicaid, CHIP, and the Health Insurance Marketplace, aiming to save $90B over 10 years. The rule strengthens oversight, requires self-reporting of overpayments, and increases transparency. Managed care stocks fell, including UNH, HUM, CVS, CLOV, CNC, MOH, ELV, and OSCR. Medicare anti-fraud efforts saved $41.9B in 2025, with a $22.30 return per dollar spent.

$OSCRHighAI 8/10

What Oscar Health (OSCR) Said on Its Q3 Earnings Call

Oscar Health (OSCR) reported Q3 improvements in medical loss ratio (84%) and SG&A expense ratio (14%). The company raised its 2026 outlook, expecting $850M-$950M in earnings from operations and $19B-$19.3B in revenue. Membership grew 27% YoY to 2.7M, but is expected to decline to 2.5M by year-end due to disenrollments. Oscar plans to expand its footprint and products for 2027.

$OSCRMed

Oscar Health Inc (OSCR) Q3 2026 Earnings Call Highlights: Record Profitability, Raised

Oscar Health (OSCR) reported Q3 2026 earnings with record profitability and raised guidance. Membership declined due to CMS reviews, with more disenrollments expected. Q4 SG&A expenses are projected to rise due to seasonal spending. CEO Mark Bertolini and CFO Richard Blackley discussed market share gains, utilization trends, and CMS program integrity initiatives. The company anticipates stable membership and market growth despite competitive pressures and regulatory uncertainties.

$OSCRHighAI 8/10

Oscar Health (OSCR) Q3 2026 Earnings Call Transcript

Oscar Health (OSCR) reported Q3 2026 revenue of $5.1B, up 70% YoY, with membership at 2.7M, up 27% YoY. Net income was $167.3M, reversing a prior-year loss. The company raised full-year guidance for revenue, earnings, and adjusted EBITDA. Management highlighted expansion into new markets, product launches, and operational efficiencies.

$HCAMed

Hospital Stocks Soared as Democrats Took Congress

HCA Healthcare (HCA) rose 10.34% to $510.70 on November 4, 2026, following Democratic gains in the U.S. election. Investors anticipate potential policy changes favoring hospitals and Medicaid insurers. Universal Health Services (UHS) and Tenet Healthcare (THC) also saw significant gains. HCA's stock is now valued at $106.68 billion, but analysts warn of potential downside risks if policy changes do not materialize.